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Objet :  
La maladie de Fabry est considérée 
comme une maladie rare, de par sa 
prévalence. Cependant, ceci cache une 
réalité clinique toute autre en raison 
du nombre de cas non dépistés. Cet 
article vise à démontrer comment les 
optométristes, via un simple examen à la 
lampe à fente, peuvent aider à améliorer 
le dépistage des patients atteints, et ce, 
dans une perspective multi-disciplinaire. 
Méthode :
Un modèle de dépistage a été instauré, 
en se basant sur l’éducation continue des 
optométristes. Les patients suspects de 
Fabry sont référés à l’École d’optométrie 
de l’Université de Montréal pour des 
tests supplémentaires. Dans le cas où 
l’histoire de cas et/ou les signes cliniques 
sont caractéristiques de la maladie de 
Fabry, un test urinaire est demandé, 
visant l’identification de biomarqueurs 
spécifiques. Si ce test s’avère positif, le sujet 
est alors référé à un spécialiste des maladies 
génétiques pour un test d’ADN et un suivi 
médical de sa condition. 
Résultats : 
Des activités de formation continue ont 
été réalisées à travers tout le Québec, 
rejoignant près de 60% des optométristes. 
Après 16 mois d’implantation, ce  
modèle a permis l’identification de 10 
suspects. De ce nombre, 2 patients 
Fabry ont été diagnostiqués, ce qui a 
conduit également à l’identification de 
la maladie chez 5 de leurs proches. Deux 
autres patients, atteints de Fabry mais 
sans suivi médical depuis des années, 
ont été à nouveau pris en charge par le 
médecin spécialiste.  À ce jour, en raison 
de l’implication des optométristes, 7 
nouveaux patients ont donc été dépistés 
et diagnostiqués alors que 2 reçoivent à 
nouveau les soins appropriés. 
Conclusion :  
En se basant sur les résultats obtenus, 
le modèle de dépistage mis en place a 
été évalué comme positif. Il confirme 
le rôle crucial des optométristes dans 
le dépistage des maladies systémiques 
ayant des implications oculaires.  
L’éducation continue est essentielle à 
la remise à jour et en perspective de 
notions apprises il y a longtemps mais 
qui ne se rencontrent pas au quotidien 
dans les pratiques. De plus, ceci suggère 
que l’optométriste peut être impliqué 
dans des équipes multidisciplinaires 
visant le dépistage de patients à risque 
et de maladies,  notamment celles qui 
entraînent des manifestations oculaires. 
By Langis Michaud 
& christiane auray-BLais
introduction
Although Fabry disease has  been known for more than a 
century (1898), this lysosomal storage 
disorder remains poorly recognized. 
With a prevalence of  1/40,000 to 
1/117,000 live male births,1 Fabry 
is considered one of  7,000 known 
rare diseases that exist in the US and 
reported. However, this number 
of  patients seems to be underesti-
mated.3 
Many heterozygous subjects are  
affected without being diagnosed, 
 no one seeing the globality of   
their symptoms. These are quite 
variable and unspecific, often leading 
to confusion with rheumatoid 
diseases or chronic inflammatory 
conditions.4 In some cases, the 
condition remains subclinical or  
is not characteristic of  the full 
spectrum of  the disease. A typical 
patient’s odyssey means multiple 
visits to more than ten different 
medical specialists before he or  
she achieves a confirmatory 
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Purpose:
Fabry disease is considered a rare disease,
based on its prevalence. It is recognized,
however, that there are many individuals
aff ected who are unscreened. This article
aims to demonstrate how optometrists
can help to defi ne improved ways to
screen patients aff ected by this rare
metabolic disorder, in a multidisciplinary
perspective
Methods:
A screening model, based on continuous
education for optometrists  was
developed. Under this model, suspect
patients identifi ed by optometrists are
referred to Université de Montréal's vision
clinic (EOUM) for further testing and
assessment. Should ocular manifestations
and/or case history prove relevant to
these rare diseases, a urinary test is then
performed to fi nd related biomarkers. 
When suspicions narrow to probable
Fabry disease, the subjects are referred 
to metabolic disorder specialists for
complete DNA testing and medical
follow-up of their condition. 
Results: 
Continuous education lectures were
given across Quebec, reaching nearly
60% of the province’s optometrists. 
Sixteen months following the model's
implementation, ten suspected patients 
were referred. Of these, two new Fabry 
patients were confi rmed, leading to 
the diagnosis of fi ve other relatives with
the disease.  Two additional persons, 
diagnosed as Fabry patients, but lost 
to medical follow-up for many years, 
were once again placed under the care
of Fabry experts. To this point, because
of optometric involvement, seven new 
patients of Fabry were diagnosed and two
were brought back under experts care. 
Conclusion:
Continuous education lectures were
given across Quebec, reaching near
60% of the province’s optometrists.
Sixteen months following the model's
implementation, ten suspected patients
were referred. Of these, two new Fabry
patients were confi rmed, leading to 
the diagnosis of fi ve other relatives with 
the disease.  Two additional persons, 
diagnosed as Fabry patients, but lost
to medical follow-up for many years, 
were once again placed under the care
of Fabry experts. To this point, because 
of optometric involvement, seven new 
patients of Fabry were diagnosed and two
were brought back under experts care. 
Key words:  Fabry disease, screening 
program, corneal pigmentation, urine
biomarkers, lysosomal storage disorder
ABSTRACT
 diagnosis. On average, this comes 
14-16 years following the onset 
of  the fi rst symptoms,5 slightly 
sooner for symptomatic children.6
For Fabry patients, quality of  life,
is severely reduced, similar
to patients with AIDS7. Stress,
negative economic repercussions
and psychological effects that 
can lead to moderate to severe
depression can affect both 
patients and their relatives.8
Considering the life-threatening 
aspect of  the disease, methods
to improve an effective screening 
of  the suspects, at the primary 
care level, are needed. This
becomes essential to target 
specifi cally young male patients,
more affected, before any major
systemic involvement occurs.
Because ocular manifestations are
among the fi rst to appear in Fabry 
patients, early in their life,8 it 
becomes interesting to consider
optometrists as key primary care 
players to detect and screen for
Fabry disease to a greater extent.
This article aims to explain how 
it can be done effectively, in a
multidisciplinary perspective.
Fabry disease explained 
Fabry disease is an X-chromosome
linked disease, and counts 431
different mutations for the GLA
gene.9 It is characterized by a
defi ciency of  the lysosomal
enzyme alpha-galactosidase A,
(GLA or a-gal A).10 Consequently, 
normal degradation and catabolism 
processes of  membrane glyco-
sphingolipids, namely 
globotriaosylceramide (also known 
as GL-3, CTH, or Gb3) can no
longer be processed in nearly all
cells of  the human organism. 
GL-3 substrates cause deposits
within the blood vessels. Its
distribution is heterogeneous,
with a preference for organs
that naturally accumulate the
greatest amount of  it (the heart 
and kidneys)11; it also favours
the vascular endothelial cells,
renal dorsal root ganglion cells,
the cornea and the skin12. 
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During its course, the most severe
(referred to as "classic") form of  
Fabry disease leads to multiple 
organ damage but clinical
presentations typically vary from 
one patient to another (Table 1).
On the other hand, milder
or later-onset variants, with
manifestations circumscribed
to one organ, can be seen in
patients showing some residual
enzyme activity.13-14
In its classic form affecting 
hemizygotes, the severity of  the
clinical picture correlates positively 
with the person’s age6, but not 
with genotype - except where
vessel tortuosity is present.15-16
Ocular manifestations 
related to Fabry disease
Ocular manifestations can be
identifi ed very early in childhood, 
by age three15 or even earlier.17
These typically occur at the same
time as systemic symptoms appear,
especially in hemizygous patients.
Classic ocular manifestations
include vortex pigmentation
of  the cornea (verticillata), lens 
opacities (anterior whitish opacities
and posterior subcapsular cata-
ract), conjunctival vessel anomalies 
(tortuosity and micro-aneurysms)
and retinal vessel tortuosities
(Figures 1 to 4),15 although such 
manifestations do not usually 
impair vision but create visual
symptoms such as photophobia.
Systemic treatment
For decades, therapy was symp-
tomatic. Since 2001 (Europe) and
2003 (USA), enzyme replacement 
therapy (ERT) has become an
available option in the causal 
treatment, and been shown to
be clinically benefi cial.18 This
treatment helps to mitigate signs 
and symptoms of  the disease
(Table 2) and would potentially 
reduce the Gb3 deposition that 
leads to irreversible organ 
damage.9,19-20 ERT also provides
an improvement in quality of  
life.20 In addition to ERT, the most 
recent pharmacological approach 
uses genetic therapy or chemically-
induced pharmacological chaper-
ones 1-deoxygalactonojirimycin 
(DGJ) and galactose to stabilize
the human a-GAL glycoprotein
and consequently to increase
enzyme activity within lyzozomes.21
Without treatment, male Fabry 
patients usually die 20 years earlier
than the general male population,
due to renal failure, progressive 
cardiomyopathy and/or cerebro-
vascular events.22 Women also 
have a shorter life expectancy 
of  15 years compared with the 
general population.22
Table 1: Signs and symptoms associated with the classic form of Fabry’s disease
Figure 1–Typical vortex pigmentation 
of  the cornea (verticillata) and corneal haze 
surrounding the deposits.
Figure 2–Anterior whitish lens opacities 
and posterior subcapsular cataract in a 35 
year-old Fabry patient.
Symptoms (most appears in early childhood and adolescence) Signs
• Acroparesthesia (numbness, tingling
of the extremities)
• Joint and abdominal pain
• Hypohydrosis
• Fever
• Heat/exercice intolerance
• Hearing loss and vertigo
• Gastro-intestinal disturbance
or pain
• Altered temperature sensitivity
• Lethargy
• Cefalea
• Moderate to severe depression
• Angiokeratomas (bathing trunk area,
ombilicus, oral mucosa, fi ngers, thorax)
• Ocular manifestations
• Facial minor dysmorphic features
• Renal dysfunction 
• Cardiac complications
• Cerebrovascular disorders (TIA, strokes)
C A N A D I A N  J O U R N A L  O F  O P T O M E T R Y  |  R E V U E  C A N A D I E N N E  D ’ O P T O M É T R I EVOL 74  |  NO 4 201228
One way to reverse this natural
course is to implement effi cient 
screening strategies to identify 
suspects early in the disease
process, and to refer them to
Fabry specialists in a timely 
manner. Such a screening strategy 
can start with the involvement 
of  those who see these potential
patients on a daily basis. Consider-
ing that ocular manifestations are
among the fi rst to appear and the
easiest to assess,23 eye care profes-
sionals should be targeted as key 
players.16
Methods
Defi ning the model 
In 2009, a collaborative pattern for
the ocular follow-up of  diagnosed
Fabry patients, under the require-
ments of  the Canadian Fabry 
Disease Initiative, was established 
between Université de Montréal, 
École d’optométrie (EOUM), and
the genetic center of  one of  its 
university hospital (Hôpital du
Sacré-Cœur de Montréal), treat-
ing most of  the Fabry patients 
in the province. The fi rst step in
responding to CFDI's request 
was to review their requirements
for oculo-visual examination
and follow-up (time, equipment,
standards, etc.) Secondly, a faculty 
member (LM) from EOUM was 
designated to take charge of  the
project, based on expertise in 
anterior segment. The third step 
was to secure a formal referral
pathway that would function
reciprocally between EOUM
and the CFDI research team
(under Dr. Bichet, of  Hôpital du 
Sacré-Cœur de Montréal).
The fourth step was then
developed. It involved recruiting 
practising optometrists to screen
for Fabry patients on a large scale.
Several continuing education
lectures were conducted across 
the province. During these. events, 
emphasis was made on the clinical
course of  the disease (age of  
onset and natural evolution), the
systemic symptoms and ocular
manifestations related to Fabry and 
the proposed screening referral
pathway.  Written documentation 
(manuscripts, posters with photos)
and DVDs about Fabry and other
lysosomal storage disorders were
also provided as reminders for
in-offi ce use.
Under the developed model,
a patient presenting with spe-
cifi c ocular manifestations and/or
symptoms of  Fabry is considered a 
suspect. The situation is explained
to the patient who is offered to be
Table 2: Summary of the eff ects of enzyme replacement therapy (ERT) on Fabry’s patients
Symptoms ERT outcome
• Gastrointestinal disturbance /abdominal pain
• Renal function (overall)
• Proteinuria
• Cardiac complications
• Hearing
• Cerebrovascular events
• Alleviated
• Stabilize or slow the decline
• Not improved
• Benefi cial- reduction in left ventricular mass
(if hypertrophy present before tx)
• Stabilize or improve (enzyme alpha)
• No improvement if tx started after event
• Unclear to prevent stroke on long term 
Figure 3–Tortuosity and micro-aneurysms 
of  blood vessels as they can be seen in the 
conjunctiva of  a 42 year-old female patient.
Figure 4–Retinal vessel tortuosities, best 
seen in red-free photograph, in an 18 year-old 
Fabry patient.
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seen at EOUM's vision clinic for
confi rmation and further assess-
ment. If  the clinical fi ndings prove
relevant (presence of  corneal
pigmentation and at least manifes-
tation of  one systemic symptom),
or in the case of  a positive genetic 
background, a urine sample col-
lected on fi lter paper is sent to 
the CHUS Expertise Centre in
Clinical Mass Spectrometry (Dr.
Auray-Blais Waters' laboratory) for 
tandem mass spectrometry analysis 
for Gb3 levels (see below). In the
case of  patients living outside of  
Montreal area, urinary test kits
(fi lter papers and request forms)
are sent to local optometrists to be
administrated.  Based on clinical
and lab results, if  enough suspicion
points to Fabry (cornea verticillata,
systemic symptoms and positive
urinary test result for Gb3 accu-
mulation), a referral is made to the 
nearest genetic centre for complete
DNA testing and follow-up.
Ocular data collected from 
confi rmed patients are part of
the CFDI registry and constitute 
the basis of  our current longitudinal
study on ocular manifestations
related to Fabry. 
Urinary biomarker testing
A method for screening high-risk 
individuals was developed to
detect both male and female
Fabry disease patients.24 The 
methodology is reliable, effi cient 
and specifi c, if  done after the
age of  6 years. It is based on an
analysis of  urinary Gb3 using 
tandem mass spectrometry,25-26
in a laboratory in Sherbrooke, 
QC. Urinary excretion of  Gb3
is normalized to creatinine27 and
patients are always age-matched
to controls.28 Nevertheless, it must 
be taken into account that patients
with cardiac variant mutations who
have residual enzyme activity do
not excrete excessive amounts of
Gb3in their urine.
Results 
Continuous education
During the fi rst 16 months of  the 
project, 750 Quebec optometrists
(out of  1,300 – 57.6%) participated 
in continuing education events,
during evening and weekends.
Patient referrals 
The fi rst examination of  a patient 
referred to the EOUM clinic
was made in September 2009.
Since that time, 10 patients have
been seen, (Table 3), referred
by optometrists who attended
continuing education events.
The urinary test was performed 
on every suspect (6 out of  10)
who showed signs (3 suspects) 
or symptoms (3 suspects) that 
suggested Fabry. This test 
Patient
Sent
by ODs
Sex Age Corneal 
pigmentation
seen
Positive Case
History (Systemic 
symptoms)
Urinary 
test 
ordered
Patient sent 
for DNA
testing
Fabry’s
confi rmed
1 F 18 Yes–typical* Yes Yes Yes Yes
2 M 22 Yes (1) No No No No
3 F 34 No Yes Yes No No
4 F 51 No Yes Yes No No
5 M 39 No Yes Yes No No
6 M 23 Yes–typical Yes Yes Yes Yes
7 F 62 Yes (2) No No No No
8 F 51 Yes-atypical Yes(a) Yes Yes No
9 M 46 Yes (3) No No No No
10 F 35 Yes (4) No No No No
Table 3 : Demographics of the referred patients to U de M vision clinic for screening
• Typical means bilateral 
pigmentation, verticilatta
type, asymetrical
• Hudson-Stahli type of 
pigmentation- monocular-
Not related to Fabry
• Pigmentation secondary 
to amiodarone – 
symetrical OU
• Pigmentation secondary 
to chloroquine
• Pigmentation secondary 
to scarring
• Relatives aff ected (cousins)
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allowed for the detection of  2 out 
of  3 suspects who showed corneal
pigmentations and symptoms.
The discovery of  these patients 
led to cascade screening and the
detection of other Fabry patients (5)
in the family, including two young 
homozygous patients fi ve and
seven years old, respectively. The
last patient with corneal signs had
a negative result on the urinary 
test. However, because of  her
positive family background for
the disease (cousins were known
Fabry patients), she was referred 
for DNA testing which was 
also negative. 
In addition to these patients, four
additional suspects living in rural
areas were co-managed with their
local optometrists. Urinary tests
were negative for the disease
and consequently they were not 
referred for DNA testing. 
Aside from these 19 individuals
(10 suspects seen + 5 relatives
+ 4 co-managed patients), two
other patients who had been lost 
to follow-up for many years were
brought back under the care of
either Dr. Bichet’s team or a local
geneticist in Quebec City, following 
an optometric examination. 
In total, 7 new patients (2 + 5
relatives) were diagnosed as
a direct consequence of  the
screening model we have 
established, and 2 more were 
brought back under appropriate
care for their systemic condition.
Discussion
In the past, several strategies have 
been proposed to increase screening 
for patients with rare diseases.29
These strategies have included 
developing and launching an in-
teractive public website to inform
and communicate with the public
and with medical professionals; a
mail-based survey of  all primary 
care physicians of  a known area;
systematic targeted screening of
the relatives of  patients already 
diagnosed, and a newborn/popu-
lation-based urine testing program
should biomarkers be detected.
For Fabry disease in particular, 
very few other initiatives have
been implemented worldwide to
increase the screening rate for
patients. Some initiatives have 
attempted to look at specifi c
groups of  patients considered
to be "at risk" based on their
signs or symptoms. For example, 
studies have been conducted
among hemodialysis patients, 
with a positive-identifi cation
success rate of  0. 2 to 1.2%.30
A similar approach involving 
patients presenting with cryp-
togenic stroke or unexplained
left ventricular hypertrophy have
yielded a 3-6% success rate.31
 In Argentina, blood sampled on
fi lter paper (dry blood testing)
from patients with signs and
symptoms has been systematically 
sent for analysis, with a yield of  
detection of  4.96%. Using this
approach, 70 patients were found
positive for the disease within 2.5
years of  implementation of  the 
protocol.32 One other experiment 
was conducted in Germany in
2003: 615 ophthalmologists were
recruited and 125,908 patients 
were examined. Out of  these, 
44 subjects (3.5%) were suspects
and 21(1.75%) were confi rmed 
as Fabry patients. This result was
not considered as successful as
other strategies, due to the time
and effort needed to screen a small 
number of  patients.33
As mentioned previously, in order
to increase the overall positive
results from screening strategies, it 
is preferable to develop a targeted 
protocol and to constitute an
interdisciplinary group to identify 
confi rmed patients. In our case, 
several aspects of  other screening 
programs were put into place 
with the uniqueness to include
optometry in the multidisciplinary 
team and to be able to rely on 
biomarker testing at an affordable
cost, compared to the higher cost 
of  DNA testing. Referral patterns 
were set up considering available
resources.
The innovative feature of  our
approach was to involve opto-
metrists, on a large scale, as team
members for the screening effort. 
In North America, optometrists 
represent the most accessible re-
sources in primary eye care. In the
province of  Quebec specifi cally,
1,300 optometrists see 30-35%
of  the population every year.34
This high level of  population 
penetration represents a unique 
opportunity for screening a large
population for Fabry disease.
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Limitations of our analysis
We cannot estimate our rate of  
success as defined by the percentage 
of  patients screened based on 
the total number of  patients who 
consulted an optometrist who 
attended a continuing education 
event. We cannot estimate the 
male/female ratio of  patients  
who consulted with a trained 
optometrist during this 16 months 
period of  time. It is therefore 
difficult to compare our data with 
the German experiment or other 
screening projects. 
On the other hand we can roughly 
approximate the value of  the model. 
Since we know that those who 
attended continuing education. 
events represent 60% of  Quebec 
optometrists, we can assume  
that they have seen as many as  
2.4 million people, in theory, over 
the last 16 months (3 million/
year/total ODs x 60% × 1.33 
years). Considering that the 
prevalence of  Fabry is 1/200,000 
in the general population we can 
estimate that 12 Fabry patients  
(2.4 million × 1/200,000) should 
have been seen. The screening 
process helped to identify 7 
individuals who were not  
diagnosed, priorly, and 2 that were 
lost to follow-up. In such a per-
spective, 9 of  12 potential patients 
were identified. This gives an idea 
of  the value of  the screening 
effort. 
On the other hand, most of  the 
patients referred to EOUM for 
confirmation of  the disease were 
not found positive for Fabry, based 
on the lack of  symptoms or due  
to other corneal pigmentation 
causes. This suggests that the  
educational process can be  
improved, or repeated. Also,  
sensitivity of  the screening could 
be improved by modifying the 
referral criterion to only include 
patients with corneal deposits 
(unexplained by other commonly 
known drugs or other common 
causes of  corneal pigmentation) 
and the presence of  systemic 
symptoms or a family history. 
Updated Data
The continuous education  
seminars were also conducted 
across Canada. As of  December 
2012, 18 other patients and  
relatives were found by optom-
etrists and confirmed as Fabry 
patients. This brings the total of  
patient screened up to 25 in the 
last 2.5 years. 
Conclusion 
Overall, a year and a half  after 
its implementation, this screen-
ing program met its goals, as it 
involved optometry and helped 
uncover new Fabry patients  
in Quebec. 
This screening program was  
effective because it was based  
on a defined protocol, a multidis-
ciplinary approach and a major 
effort to provide up-to-date  
information to optometrists as 
primary care providers. 
Our ability to rely on an accessible 
resource, everywhere in the terri-
tory, helped immeasurably. In  
this sense, optometrists should  
be considered key players in the 
development of  any large-scale 
screening program for rare diseases 
involving ocular manifestations. 
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